Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer

• Main Authors: Tsui, D.W.Y, Murtaza, M, Wong, A.S.C, Rueda, O.M, Smith, C.G, Chandrananda, D, Soo, R.A, Lim, H.L, Goh, B.C, Caldas, C, Forshew, T, Gale, D, Liu, W, Morris, J, Marass, F, Eisen, T, Chin, T.M, Rosenfeld, N
• Other Authors: MEDICINE
• Format: Article
• Published: 2020
• Subjects: circulating tumor DNA; epidermal growth factor receptor; gefitinib; hydroxychloroquine; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; antineoplastic agent; DNA; EGFR protein, human; protein p53; TP53 protein, human; Article; cancer patient; clinical article; controlled study; drug response; EGFR gene; gene; gene dosage; gene mutation; human; longitudinal study; molecularly targeted therapy; non small cell lung cancer; overall survival; PIK3CA gene; priority journal; progression free survival; PTEN gene; tumor suppressor gene; whole genome sequencing; blood; chemistry; copy number variation; dna mutational analysis; drug resistance; genetics; lung tumor; mutation; pathology; prognosis; survival analysis; treatment outcome; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Copy Number Variations; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Hydroxychloroquine; Longitudinal Studies; Lung Neoplasms; Mutation; Prognosis; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/178087
• Institution: National University of Singapore

10.15252/emmm.201707945